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INTRODUCTION
Trimethoprim-sulfamethoxazole (TMP-SMX) is a widely 
used antibiotic in the prophylaxis and treatment of a variety 
of common infections. Hepatic injuries caused by TMP-
SMX are considered rare and are classified as unpredictable 
or idiosyncratic types of hepatotoxic reactions.1 The pattern 
of injury may be characterized by hepatocellular necrosis,1,2 
mixed hepatocellular-cholestasis,1,3,4 or cholestasis.5-7 We 
describe a case of severe and prolonged cholestasis, which 
arose 30 days after a 5-day course of TMP-SMX treatment, 
and provide a review of related cases.
CASE DESCRIPTION
A 33-year-old woman with a past history of recurrent 
urinary tract infection was treated with TMP-SMX for 5 
days. One month later, she developed malaise, fatigue, 
anorexia, nausea, vomiting, fever, jaundice, dark urine, and 
a diffuse pruriginous rash. She had been previously exposed 
to this agent in the past. She denied alcohol consumption 
and any previous comorbid condition, and she had not 
taken any other medication during the last 3 months. The 
patient was previously hospitalized in 2 other institutions. 
Laboratory tests performed during the second admission 
revealed a total bilirubin level of 26.8 mg/dL (upper normal 
limit [UNL] 1.2 mg/dL), conjugated bilirubin of 19.6 mg/
dL (UNL 0.3 mg/dL), aspartate aminotransferase (AST) 
of 154 IU/L (UNL 46 IU/L), alanine aminotransferase 
(ALT) of 63 IU/L (UNL 66 IU/L), alkaline phosphatase 
of 226 IU/L (UNL 126 IU/L), and albumin of 2.3 g/dL. 
Abdominal ultrasound and computed tomography were 
normal. Tests for antinuclear antibody, antibodies against 
hepatitis C virus, and human immunodeficiency virus 
(HIV), total anti-HBc, and hepatitis B surface antigen were 
all negative. Liver biopsy demonstrated severe cholestasis, 
with bile inside the hepatocytes and numerous bile casts 
in the canaliculi, predominantly in the pericentrilobular 
zone. Small numbers of mononuclear cells and neutrophils 
infiltrated into the vicinity of the cholestasis without any 
other inflammatory activity (portal or periportal) or fibrosis. 
The liver architecture was intact (Figure 1). As the jaundice 
Figure 1 - Severe cholestasis with bile inside the hepatocytes and numerous 
bile casts in the canaliculi, predominantly in the pericentrilobular zone; small 
numbers of mononuclear cells and neutrophils infiltrate into the vicinity of 
the cholestasis (HE, × 400)72
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persisted, the patient developed pruritus and lost 15 Kg over 
2 months. The patient was then referred to our institution for 
continued investigation. At that time, the total bilirubin was 
14.2 mg/dL, with a conjugated bilirubin level of 13.3 mg/
dL, alkaline phosphatase of 1,273 IU/L, gamma glutamyl 
transpeptidase (GGT) of 877 IU/L (UNL 43 IU/L), AST of 
147 IU/L, ALT of 103 IU/L, International Normalized Ratio 
(INR) of 1.4, albumin of 2.6 g/dL, and globulins of 3.4 g/
dL. The patient exhibited normocytic and normochromic 
anemia (hemoglobin 10.8 g/dL), with normal white blood 
cell (without eosinophilia) and platelet counts. Plasma 
levels of amylase, lipase, urea, creatinin, and glucose were 
normal. Serologies for hepatitis A, B, and C and anti-HIV 
were negative, as were the autoantibodies (antimitochondrial, 
anti-smooth muscle, anti-liver kidney muscle [LKM]-1, 
antinucleus, antithyroid peroxidase, and antithyroglobulin). 
Caeruloplasmin, ferritin, alpha-1-antitrypsin, TSH, free 
thyroxine (fT4), IgG, IgM, IgA and alpha-fetoprotein 
levels were all normal. Upper digestive endoscopy 
and endoscopic retrograde cholangiopancreatography 
(ERCP) demonstrated no abnormalities. Abdominal 
ultrasound revealed non-specific splenomegaly. Liver 
biopsy was repeated with equivalent results. The pruritus 
was unresponsive to cholestyramine associated with 
dexclorfeniramine, but it was successfully treated with 
cholestyramine and hydroxyzine. The patient presented 
with slow and progressive improvement of all clinical and 
laboratory parameters, with complete normalization of the 
bilirubin levels in 8 months, alkaline phosphatase in 16 
months, and GGT in 35 months (Figure 2). She regained 
weight and is currently asymptomatic and doing well. The 
patient also exhibited normal liver function during a follow-
up period of 5 years after symptom onset.
DISCUSSION
We report a case of severe cholestasis accompanied by 
important systemic repercussion, as evidenced by weight 
loss (15 Kg in 2 months), hypoalbuminemia, anemia, and a 
protracted course of disease. The exhaustive investigation of 
other etiologies of liver damage strongly suggested a causal 
association between TMP-SMX and the hepatic lesion in this 
case. Liver biopsy demonstrated cholestasis with minimal 
lobular inflammatory activity and necrosis.
Drug-induced liver injury due to TMP-SMX is rare 
and is classified as either an unpredictable or idiosyncratic 
type of hepatotoxic reaction. The pattern of injury may 
be characterized by hepatocellular necrosis,1,2 mixed 
hepatocellular-cholestasis,1,3,4 or cholestasis.5-7 The majority 
of the reported cases of TMP-SMX-induced cholestasis were 
reviewed and are summarized in Table 1.
In previous reports, TMP-SMX-induced intrahepatic 
cholestasis was associated with minimal hepatocellular 
inflammation or necrosis, symptom onset of between a 
few days and a month after the beginning of therapy, and a 
clinical course that usually subsides within a few months.5,8-11 
The etiologic role of TMP-SMX has been confirmed in a 
few cases by either inadvertent or deliberate rechallenge.3,8,10 
In the present case, rechallenge was not accomplished 
because of the clinical severity and prolonged course of the 
disease. The time interval between drug discontinuation and 
initiation of symptoms in the present case was quite long 
(30 days). However, we could not rule out the possibility of 
the presence of mild symptoms before they became severe 
enough to be noticed by the patient. Furthermore, the latency 
period between initial ingestion of the drug and hepatic 
manifestations could range from 5 to 90 days.12
A few reports of prolonged cholestasis induced by 
TMP-SMX have already been published.6,7,13 Muñoz et al. 
described a case of intrahepatic cholestasis associated with 
prominent hepatocyte lysosomal inclusions suggestive of 
phospholipidosis by electron microscopy, and of severe 
pruritus that lasted 8 months. The symptoms eventually 
led to the initiation of plasmapheresis.7 Kowdley et al. 
reported two cases of severe, prolonged cholestasis in 
which bilirubin normalized within 11-12 months and mild 
alkaline phosphatase and GGT level abnormalities lasted for 
approximately 2 years.6
Two cases of TMP-SMX-induced cholestatic liver 
damage with ductopenia (vanishing bile duct syndrome) 
have also been reported.14,15 Yao et al. reported one such case 
in which jaundice appeared after a 5-day course of therapy 
and progression to liver failure led to liver transplantation 
9 months after the onset of the symptoms.14 The possibility 
of such clinical evolution should alert physicians to the  Figure 2 - Evolution of alkaline phosphatase, gamma glutamyl transpeptidase 
(GGT), and total bilirubin; UNL: upper normal limit73
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Table 1 - Cases of Trimethoprim-sulfamethoxazole (TMT-SMX) induced cholestasis
Publication Age Sex
Time interval between the use of 
TMT-SMX and the beginning of 
the symptoms
Total bilirubin
(mg/dL)
Time interval between the 
interruption of TMT-SMX and 
normalization of bilirubin
Rechallenge
Ogilvie et al., 1980 (8) 70 F Just after a 7-day course 22.3 6 months
Yes, inadvertently, 
positive
Nair et al., 1980 (9) 61 M After 1 month on therapy 8.8 1 month No
Steinbrecher and 
Mishkin, 1981 (10) 53 F Just after a 10-day course 9 1 month
Yes, inadvertently 
and after informed 
consent, both 
positive
Coto et al., 1981 (11) 55 M In the 3rd week of therapy 7.1 1.5 month No
Abi-Mansur  et al., 
1981 (5) 52 F In the 7th day of therapy 11.2 3 months No
Muñoz et al., 1990 (7) 60 F In the 4th day of therapy 37 8 months No
Kowdley et al., 1992 (6) 48 F In the 10th day of therapy 34.8 11 months No
Kowdley et al., 1992 (6) 43 F In the 7th day of therapy 36.8 12 months No
Altraif et al., 1994 (14) 30 M In the 4th day of therapy 2.5 Few weeks, but pruritus persisted 
for longer than one year
No
Ruiz-Irastorza et al., 
1996 (13)
38 F 1 day after a single dose 10.7 5 months: total bilirubin 1.5
One year: total bilirubin normal
No
Yao et al., 1997 (15) 57 M In the 5th day of therapy 40.4
It did not normalize. Because of 
clinical deterioration, the patient 
underwent ortthotopic liver 
transplantation 9 months after the 
beginning of symptoms
No
Kouklakis et al., 
2007 (4)
30 M 11 days after a 
15-day course  
6.9 40 days No
F: female; M: male
potentially serious cholestatic-pattern of hepatotoxicity 
associated with this commonly used drug.
The present report and other similar cases demonstrate 
that cholestasis can be the most prominent feature of 
TMP-SMX-induced liver damage. The high frequency 
of TMP-SMX prescription contrasts with the rarity of 
well-documented examples of drug-related cholestasis or 
hepatic damage due to the use of TMP-SMX. Nevertheless, 
the present case and other previous cases emphasize the 
importance of considering drug-induced liver disease during 
differential diagnosis of patients receiving this drug. This is 
particularly critical since TMP-SMX administration must be 
stopped immediately in order to improve the outcome despite 
the rare need for patients to require liver transplantation as a 
consequence of dug-induced hepatotoxic injury.15
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